Of note, a more recent trial, the ODYSSEY-J IVUS (Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome) trial [ 111 ], represents a deviation from the amount of evidence in favor of PCSK9-i drugs since it demonstrated that in patients with ACS and statin-resistant hypercholesterolemia, alirocumab produced a numerically greater reduction in total atheroma volume at week 36 compared with standard therapy, although the difference did not reach statistical significance.
1
—
—